ClinTex’s Ongoing CTi Presale Gives Unparalleled Access to the $350bn Medical Trials Market
Photo: ClinTex
This content is provided by a sponsor
With the current global pandemic sweeping the globe, the fiscal impact can be seen everywhere, and in industries once considered safe havens, impacts expected to last a decade are commonplace. From the tech moguls of Silicon Valley, to the high-tech production centers of Europe, It is clear that the world is crying out for innovation in a time where opportunities are few and far between.
To this end, London-based company ClinTex says it has the answer to a disempowered financial ecosystem. It looks perfectly poised to provide a solution not only to medical patients worldwide, but the healthcare industry as a whole and of course, to provide a potentially amazing return to its stakeholders through its CTi token pre-sale, which is currently ongoing.
Pharmaceutical Industry Inefficiencies
The value proposition for ClinTex lies in one simple observed fact – for an industry that is considered cutting edge, the Pharmaceutical industry is fraught with inefficiency. In such a notable time for health globally, these inefficiencies are having widespread consequences:
Large Time Delays – A promising medicine can take up to 15 years to get to patients, with untold amounts of heartache and emotional trauma for families and individuals alike. The CTi platform will help issues to be detected and prevented generating millions in savings.
High Testing Cost – It now costs over $2,500,000,000 to get a drug to market, with every day in clinical trials costing up to $8,000,000 in revenue erosion for each day a new medicine is delayed – And that cost gets passed onto the patient. CTi will vastly reduce costs, helping deliver medicines not just faster, but cheaper to those who need it.
Poor Data Quality – With the Clinical Data Visualisation App in CTi, fundamental and systemic errors in data can rapidly be detected and addressed, leading to greater insights and far better data application. Developments like this lead to greater industry progression long-term.
Little-To-No Collaboration – Currently, there exists almost no collaboration between industry players. This problem has been magnified with the COVID-19 pandemic. The opportunities for efficiency by extracting the intelligence and insights inherent in clinical data across the globe are many – This is perhaps one of the largest benefits – As the ecosystem grows in value, more partners sign up, and the value increases.
COVID-19 & CTi – Returns to Rival DeFi?
With the current pandemic raging on, and 142 COVID-19 vaccines currently awaiting trials, there has never been a better time for CTi’s implementation in the industry. We are already seeing haphazard attempts at research collaboration in the hunt for a COVID-19 vaccine and treatments. And with these spends potentially reaching into the trillions, CTi could represent the next generation of innovative profits to follow DeFi in re-igniting the crypto wave not seen since the ICO boom of 2017.
The CTi token pre-sale runs until 25th September 2020, and CTi can be purchased for a 50% discounted price of 0.05$ by visiting this link. $1m USD in CTi is available for purchase, which is equivalent to 10% of the total CTi supply. Leftover tokens will be burned, and the main sale commences in October 2020 where tokens will be available for $0.10.
ClinTex is doing what all companies strive to do in times of hardship – To innovate. And with a market valued at $350,000,000,000 per year, the possibilities are endless. Now is the time. Be a part of this exciting project and enjoy discounts on one of the industry’s most promising projects this year.
Disclaimer: This publication is sponsored. Coinspeaker does not endorse or assume responsibility for the content, accuracy, quality, advertising, products, or other materials on this web page. Readers are advised to conduct their own research before engaging with any company mentioned. Please note that the featured information is not intended as, and shall not be understood or construed as legal, tax, investment, financial, or other advice. Nothing contained on this web page constitutes a solicitation, recommendation, endorsement, or offer by Coinspeaker or any third party service provider to buy or sell any cryptoassets or other financial instruments. Crypto assets are a high-risk investment. You should consider whether you understand the possibility of losing money due to leverage. None of the material should be considered as investment advice. Coinspeaker shall not be held liable, directly or indirectly, for any damages or losses arising from the use or reliance on any content, goods, or services featured on this web page.
